Ligand Reports Second Quarter 2024 Financial Results — Aug 6th, 2024

Conference call at 4:30 p.m. Eastern Time today JUPITER, Fla., August 06, 2024--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Li...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...